2023
Chapter 3 Ovarian carcinosarcoma
Tymon-Rosario J, Chui M, Santin A. Chapter 3 Ovarian carcinosarcoma. 2023, 41-54. DOI: 10.1016/b978-0-323-82938-0.00003-3.Peer-Reviewed Original ResearchHigh-grade serous ovarian carcinomaSurvival of womenEpithelial ovarian cancerSerous ovarian carcinomaEpithelial-mesenchymal transitionCarcinosarcoma patientsGynecologic tractHistologic subtypeOvarian carcinosarcomaAggressive diseaseAggressive malignancyCarcinoma componentOvarian tumorsClinical managementOvarian carcinomaClinical trialsOvarian cancerSarcomatous elementsAggressive natureCarcinosarcomaTumorsDiseaseSurvivalMolecular studiesPatients
2022
Impact of radiotherapy delay following biopsy for patients with unresected glioblastoma.
Gao S, Jin L, Moliterno J, Corbin ZA, Bindra RS, Contessa JN, Yu JB, Park HS. Impact of radiotherapy delay following biopsy for patients with unresected glioblastoma. Journal Of Neurosurgery 2022, 138: 610-620. PMID: 35907197, DOI: 10.3171/2022.5.jns212761.Peer-Reviewed Original ResearchConceptsWeeks of biopsyOverall survivalCox proportional hazards regression modelingProportional hazards regression modelingNational Cancer DatabaseInitiation of radiotherapyKaplan-Meier methodWorse overall survivalWilcoxon rank sum testEffects of confoundersRank sum testUnresected diseaseAdjuvant radiotherapyConcurrent chemotherapyMedian intervalMultivariable analysisRadiotherapy delayCancer DatabaseClinical dataBiopsyPatientsLate initiationAggressive natureRadiotherapyPotential association
2020
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Ilyas S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology & Hepatology 2020, 17: 557-588. PMID: 32606456, PMCID: PMC7447603, DOI: 10.1038/s41575-020-0310-z.Peer-Reviewed Original ResearchConceptsPrimary liver cancerExpert consensus statementCancer-related deathCell of originBiliary malignant tumorsStudy of CholangiocarcinomaGastrointestinal malignanciesHistological confirmationAvailable therapiesBiliary treeNew diagnostic toolsSilent presentationPatient outcomesConsensus statementMalignant tumorsLiver cancerCholangiocarcinomaAggressive natureAlarming mortalityCurrent diagnosisMolecular alterationsNon-invasive approachTumorsDiagnostic toolTherapy
2019
Hyperleukocytosis in Cancer Patients
Gowda L, Hosing C. Hyperleukocytosis in Cancer Patients. 2019, 1147-1153. DOI: 10.1007/978-3-319-74588-6_94.Peer-Reviewed Original ResearchTumor lysis syndromeWhite blood cellsDefinitive therapyPeripheral blood white blood cellsBlood white blood cellsSupportive care measuresHigh WBC countSymptomatic hyperleukocytosisLysis syndromeCoagulation abnormalitiesIntravascular coagulationLethal complicationAvoidable complicationsPoor prognosisCancer patientsWBC countCare measuresSymptomatic courseMalignant cloneHyperleukocytosisAggressive natureTherapeutic interventionsBiologic driversComplicationsBlood cellsHyperleukocytosis in Cancer Patients
Gowda L, Hosing C. Hyperleukocytosis in Cancer Patients. 2019, 1-7. DOI: 10.1007/978-3-319-74698-2_94-1.Peer-Reviewed Original ResearchTumor lysis syndromeWhite blood cellsDefinitive therapyPeripheral blood white blood cellsBlood white blood cellsSupportive care measuresHigh WBC countSymptomatic hyperleukocytosisLysis syndromeCoagulation abnormalitiesIntravascular coagulationLethal complicationAvoidable complicationsPoor prognosisCancer patientsWBC countCare measuresSymptomatic courseMalignant cloneHyperleukocytosisAggressive natureTherapeutic interventionsBiologic driversComplicationsBlood cells
2016
Chapter 20 Management of Melanoma Therapy-Associated Toxicities
Weiss S, Kavecansky J, Pavlick A. Chapter 20 Management of Melanoma Therapy-Associated Toxicities. 2016, 299-319. DOI: 10.1016/b978-0-12-803508-5.00020-2.Peer-Reviewed Original ResearchSkin cancer-related deathsAntitumor immune responseUnique adverse eventsCancer-related deathPatient survival outcomesNew therapeutic strategiesQuality of lifeMelanoma driver mutationsChapter 20 ManagementAdverse eventsAdvanced melanomaSurvival outcomesImmune responseTherapeutic strategiesInitial approvalAggressive natureSkin cancerNew casesPatient safetyDriver mutationsMelanomaSignificant delayTherapyCliniciansVast majority
2004
Automated Quantitative Analysis of HDM2 Expression in Malignant Melanoma Shows Association with Early-Stage Disease and Improved Outcome
Berger AJ, Camp RL, DiVito KA, Kluger HM, Halaban R, Rimm DL. Automated Quantitative Analysis of HDM2 Expression in Malignant Melanoma Shows Association with Early-Stage Disease and Improved Outcome. Cancer Research 2004, 64: 8767-8772. PMID: 15574789, DOI: 10.1158/0008-5472.can-04-1384.Peer-Reviewed Original ResearchConceptsMurine double minute 2Double minute 2Protein expressionMalignant melanomaMinute 2Early-stage diseaseTissue microarray cohortPotential tissue biomarkersCutaneous malignant melanomaValuable prognostic toolNormal skin samplesSkin cancer deathsMicroarray cohortAdvanced melanomaMetastatic lesionsCancer deathPrimary melanomaImproved outcomesExpression of HDM2Tissue biomarkersPrognostic toolBetter outcomesMelanoma lesionsAggressive natureMelanomaMUC1 and MUC2 in pancreatic neoplasia
Levi E, Klimstra D, Adsay N, Andea A, Basturk O. MUC1 and MUC2 in pancreatic neoplasia. Journal Of Clinical Pathology 2004, 57: 456. PMID: 15113850, PMCID: PMC1770304, DOI: 10.1136/jcp.2003.013292.Peer-Reviewed Original ResearchConceptsIntraductal papillary mucinous neoplasmPancreatic neoplasiaMarker of aggressive phenotypeSpread of carcinoma cellsIntestinal IPMNsPapillary mucinous neoplasmAggressive pancreatic tumorsCell-stroma interactionsIndolent tumorsProtective barrier functionTumor suppressor roleIndolent phenotypePancreatic tumorsColloid carcinomaMucinous neoplasmsPrognostic valueVascular spreadAggressive phenotypeAggressive natureCell-cellCarcinoma cellsCancer progressionSignal transducerIndole pathwayNeoplasia
2003
Subcutaneous metastasis at a surgical drain site after the resection of pancreatic cancer
St. Peter SD, Nguyen CC, Mulligan DC, Moss AA. Subcutaneous metastasis at a surgical drain site after the resection of pancreatic cancer. Journal Of Gastrointestinal Cancer 2003, 33: 111. PMID: 14716058, DOI: 10.1385/ijgc:33:2-3:111.Peer-Reviewed Original ResearchConceptsCurative intentPancreatic cancerSurgical drain siteImpact of surgeryTumor growth characteristicsCutaneous recurrenceCutaneous metastasesPalliative procedureSkin metastasesSubcutaneous metastasesSurgical drainsTumor burdenSurgical controlPeritoneal cavityUnusual caseDrain siteResectionAggressive natureMetastasisRecurrenceCancerDiseaseRare eventComplicationsSurgery
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply